June 20, 2022
BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic® in Ocudose®) and has begun commercialization activities.
Preservative-free Timolol Maleate Ophthalmic Solution, USP is supplied in single-dose vials, as a sterile, isotonic, buffered, aqueous solution of timolol maleate and is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Preservative-free Timolol Maleate Ophthalmic Solution, USP in the unit dose vial may be used when a patient is sensitive to:
- the preservative in Timolol Maleate Ophthalmic Solution, USP,
- benzalkonium chloride, or
- when the use of a preservative-free topical medication is advisable.
“We are pleased to have added Timolol Maleate Ophthalmic Solution, USP to our generics portfolio,” stated Daniel Carbery, President and CEO of Amring. “We are continuing to realize the benefits of this portfolio addition and to serving our patients and customers with high quality and affordable medicines.”
About Amring Pharmaceuticals Inc.
Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. The company is a subsidiary of a privately held global specialty pharmaceutical company based in the Netherlands. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
This press release contains forward-looking statements, including, without limitation, statements related to Amring’s business developments and the implementation of Amring’s strategic initiatives. Because these statements reflect Amring’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring, and other factors that could affect Amring’s business and financial performance. Amring does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Amring Pharmaceuticals Inc.
Marina Volin, Esq.
VP, General Counsel